E pigenetic regulation of gene expression is mediated by DNA methylation as well as by modification of nucleosome structure and cofactor recruitment through histone modifications. Specific methylation and acetylation of histone lysine residues, which comprise the so-called histone code, are marks of different chromatin states related to the expression of neighboring genes and the activity of promoters and enhancers. Histone acetylation and methylation, along with their role in regulating transcription has been known since the 1960s. The enzymes that make these modifications can be thought of as chromosome writers, whereas the enzymes that remove these marks can be referred to as chromosome erasers. Another set of proteins sense these marks and alter gene expression, which can be termed chromosome readers. Histone acetylation is performed by members of the histone acetyltransferase gene family, which use acetyl-CoA as a cofactor to modify specific ε-amino group of lysine residues on different histone proteins. This modification eliminates lysine's positive charge and reduces the affinity of the histone for DNA, which can result in a more relaxed chromatin conformation that can facilitate the recruitment of DNA binding effector proteins. Thus, histone acetylation is most often associated with increased transcriptional activity, and in the most extreme case, acetylation of lysine 16 on histone H4 (H4K16ac) is involved in the switch from inactive heterochromatin to euchromatin. 1 Histone acetylation is reversible, allowing for environmental and developmental gene regulation, usually repression; and this process is performed by members of the histone deacetylase (HDAC) gene family. There are 5 phylogenetic classes of HDACs in mammalian cells comprising 18 genes in humans. The classical HDAC genes in classes I, IIA, IIB, and IV are zinc-dependent enzymes, whereas the class III genes are the sirtuins, which are NAD+-dependent enzymes. 2 Acetylation is widespread in cell proteins, and HDACs can deacetylate other proteins aside from histones. Because protein acetylation controls many features of cell physiology and proliferation, there are many HDAC and sirtuin inhibitors in use in the laboratory as well as in the clinical pipeline, with 2 drugs, vorinostat and romidepsin, approved for oncology, and a host of other drugs in clinical trials for a range of diseases. 3 Completing the regulatory circuit, acetylated histones are read by a large family of bromodomain and extraterminal domain (BET) proteins, which directly bind to acetylated lysine residues on histones. BRD4 (bromodomain-containing protein 4) is 1 well-studied BET protein that has several activities, including acting as a transcription factor, bookmarking the chromatin during mitosis to activate specific genes, and acting as a scaffold to recruit other factors to the chromatin that play roles in RNA transcription, elongation, or splicing. 4
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In this issue of ATVB, a team led by Mishra from Wake Forest School of Medicine demonstrated a role for HDAC9, a class IIA enzyme, in mouse macrophage polarization, cholesterol efflux, and atherosclerosis. 5 Class IIA HDAC proteins contain an N-terminal domain that regulate nuclear-cytoplasmic shuttling, which is modulated by phosphorylation and subsequent binding of 14-3-3 proteins. 2 One impetus for the study of HDAC9 is that various common single nucleotide polymorphisms (SNPs) in HDAC9 introns have been associated with stroke (2 independent studies), retinopathy, obesity-related traits, ulcerative colitis, and male pattern baldness in genome-wide association studies (www.genome.gov/gwastudies, accessed 7/17/14); however, the functional mechanisms by which these SNPs alter these traits has not been described. HDAC9 is expressed highly in muscle and brain, and in addition to histone deacetylation and its role in epigenetics, HDAC9 binds to and represses the activity of the transcription factor MEF2, 6 and it also binds to TRIM29, altering its association with p53 and regulating cell proliferation. 7 HDAC9 knockout mice were created in the Olson laboratory, and although fertile and normal at birth, these mice develop cardiac hypertrophy on aging and are sensitized to pressure overload. 8 Others have shown that HDAC9-deficient mice exhibit polydactyly, resistance to colitis, and resistance to obesity and glucose intolerance on high-fat diet feeding. [9] [10] [11] In the present study, Cao et al 5 crossed the HDAC9-deficient mice from the Olson laboratory to low-density lipoprotein receptor (LDLr)-deficient mice to create the double knockout (DKO) mice. After feeding a high-carbohydrate diet with 0.1% cholesterol, the DKO mice, compared with the single LDLr knockout, had decreased lesions in the aortic root, arch, and descending aorta, which was associated with a modest shift of plasma cholesterol from very-low-density lipoprotein to LDL and a modest reduction in plasma triglycerides. Targeted gene expression studies in the aortic roots showed that ABCA1, ABG1, and arginase-1 were induced in the DKO, whereas interleukin-1β and MCP1 were repressed. To see whether these effects were mediated by HDAC9 expression in leukocytes, they performed transplantation of single LDLr knockout or DKO bone marrow cells into irradiated LDLr-deficient hosts, which confirmed the same antiatherogenic effect for the mice receiving the DKO donor cells. Through in vitro studies, HDAC9-deficient versus wild-type macrophages were found to have increased ABCA1 and ABCG1 expression, as well as cholesterol efflux to apolipoprotein A1 (ABCA1-dependent) and high-density lipoprotein. Using chromatin immunoprecipitation followed by polymerase chain reaction, the increased macrophage expression of ABCA1 and ABCG1 in the HDAC9 knockout cells was associated with increased H3 and H4 acetylation at their respective promoters, without any histone acetylation changes observed for the scavenger receptor A promoter, a gene whose expression was not altered by HDAC9 deficiency. Macrophages from the HDAC9-deficient mice were also less responsive to lipopolysaccharide stimulation in their release of proinflammatory cytokines; and, target gene quantitative polymerase chain reaction showed that these HDAC9-deficient cells had increased expression of markers for alternatively activated M2 macrophages and decreased expression of M1 markers. Thus, HDAC9 deficiency results in macrophages that are polarized for promoting inflammation resolution and reverse cholesterol transport, which can put the brakes on atherosclerosis progression and promote lesion regression.
Previously, via the use of various inhibitors and gene knockouts, HDACs have been found to have both positive and negative effects on toll-like receptor signaling and innate immunity. 12 The current study demonstrates clearly that HDAC9 has a positive effect on toll-like receptor signaling, as the HCAD9-deficient macrophages are less sensitive to lipopolysaccharides. In contrast to the current study, a prior study found that chronic intraperitoneal injection of the HDAC inhibitor trichostatin (TSA), which inhibits HDACs in class I, IIA, and IIB, led to increased aortic root lesions in LDLr-deficient mice fed a high-cholesterol diet. 13 It is easy to reconcile this difference because HDAC9 deficiency is quite specific compared with the TSA-mediated inhibition of many HDACs. TSA has also been shown to upregulate the expression of the macrophage scavenger receptors scavenger receptor A and CD36 and increase oxidized LDL uptake, 13, 14 whereas HDAC9 deficiency had no effect on macrophage expression of scavenger receptor A. 5 One of the remaining questions about the current study is whether the anti-inflammatory and antiatherogenic effects of HDAC9 deficiency are mediated primarily through histone modification or via deacetylation of other effector proteins. In conclusion, Cao et al demonstrated the potential to use HDAC9 inhibition to prevent inflammation and atherosclerosis, and as more specific HDAC9 inhibitors are developed, these will be attractive drugs to evaluate.
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